Evidence map›Paper›PMID 36203881›Full record

ArticleAdvanced therapeutics2022

Recent Developments in Drug Delivery for Treatment of Tuberculosis by Targeting Macrophages.

Anirudh Gairola, Aaron Benjamin, Joshua D Weatherston, Jeffrey D Cirillo, Hung-Jen Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Mannose Derivatives as Anti-Infective Agents.International journal of molecular sciences · 2025
    Review
  4. Review
  5. Mannosamine-Modified Poly(lactic-Bioconjugate chemistry · 2025
    Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anirudh GairolaDepartment of Chemical Engineering, Texas A&M University, College Station, Texas, USA.
Aaron BenjaminDepartment of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, Bryan, Texas, USA.
Joshua D WeatherstonDepartment of Chemical Engineering, Texas A&M University, College Station, Texas, USA.
Jeffrey D CirilloDepartment of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, Bryan, Texas, USA.
Hung-Jen WuDepartment of Chemical Engineering, Texas A&M University, College Station, Texas, USA.

Funding

Design of hetero-multivalent targeted liposome for combating intracellular Mycobacterium tuberculosisR21AI149383 · NIAID · TEXAS ENGINEERING EXPERIMENT STATION · PI CIRILLO, JEFFREY D., WU, HUNG-JEN · 2020 to 2021
$416k
NIAID NIH HHS R21 AI149383
6 · The paper itself

Abstract

Tuberculosis (TB) is among the greatest public health and safety concerns in the 21

Indexed as

Drug deliveryMacrophage targetingNanocarrierNanomedicineTuberculosis

Identifiers

PMID36203881
PMCPMC9531895

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.